Alexion Pharmaceuticals, Inc.
(NASDAQ : ALXN)

( )
ALXN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc. 4.23%75.931.0%$2028.13m
AMGNAmgen, Inc. 5.15%208.481.3%$944.46m
REGNRegeneron Pharmaceuticals, Inc. 5.22%473.002.6%$802.29m
BIIBBiogen, Inc. 6.53%316.131.5%$751.59m
VRTXVertex Pharmaceuticals, Inc. 6.76%231.921.9%$564.30m
MRNAModerna, Inc. 1.43%30.480.0%$562.64m
ILMNIllumina, Inc. 2.67%276.233.5%$478.28m
ALXNAlexion Pharmaceuticals, Inc. 3.87%87.262.0%$278.63m
AAgilent Technologies, Inc. 2.84%72.741.6%$236.92m
EXASEXACT Sciences Corp. 0.92%58.4321.0%$200.66m
INCYIncyte Corp. 4.66%72.172.5%$176.73m
SGENSeattle Genetics, Inc. 5.51%115.296.1%$169.71m
BMRNBioMarin Pharmaceutical, Inc. 3.75%82.494.3%$160.87m
NVAXNovavax, Inc. 9.58%14.30114.7%$133.52m
CODXCo-Diagnostics, Inc. -10.38%8.200.0%$107.45m

Company Profile

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Boston, MA.